IP Library Granted Patent US 8,895,299
Granted Patent B2
US 8,895,299 · App. 12/823,960 · Granted Nov 25, 2014

Method for expansion of stem cells

Inventor: Neil H. Riordan (Tempe, AZ)
Assignee: XON Cells, Inc.
A61K8/982A61Q7/00A61Q19/08A61K35/28C12N2502/02A61K35/50A61K35/51A61K35/44C12N5/0018A61K38/1825
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,299
App. No.
12/823,960
Granted
Nov 25, 2014
Kind
B2
Abstract

A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population.

Claims (11)

1. A method for the expansion or growth of stem cells without substantially inducing differentiation, the method comprising:

collecting cord blood from a human umbilical cord;

isolating CD34+ cells from the cord blood;

producing live placenta conditioned medium (LPCM) by incubating whole human placenta in a Dulbecco's modified Eagle medium (DMEM) in a sterile container, wherein the whole placenta is submerged;

isolating the LPCM; and

contacting at least one CD34+ cell with a supplemented DMEM comprising the LPCM and a cytokine cocktail comprising 20 ng/ml IL-3, 250 ng/ml IL-6, 10 ng/ml stem cell factor, 250 ng/ml thrombopoietin, and 100 ng/ml Flt-3L, wherein the concentration of the LPCM in the supplemented DMEM is 50%.

2. The method of claim 1 , wherein isolating CD34+ cells comprises a method selected from the group consisting of fluorescence activated cell sorting, magnet activated cell sorting, counterflow centrifugal elutriation, equilibrium density centrifugation, velocity sedimentation at unit gravity, and T lymphocyte depletion.

3. The method of claim 1 , wherein incubating whole human placenta in a DMEM comprises a period of at least 24 hours.

4. The method of claim 1 , further comprising decontaminating the isolated LPCM by a method selected from the group consisting of filtration, UV irradiation, X-ray sterilization, ozonation, and hyperthermia.

5. The method of claim 1 , wherein contacting at least one CD34+ cell with a supplemented DMEM comprises a period of at least 24 hours.

6. The method of claim 1 , wherein the supplemented DMEM comprises a growth factor selected from the group consisting of, IL-1, IL-7, G-CSF, GM-CSF, Epo, FGF-1, FGF-2, FGF-4, FGF-20, IGF, EGF, NGF, LIF, PDGF, bone morphogenic proteins (BMP), activin-A, VEGF, and forskolin.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Oct 22, 2014
From: MEDISTEM INC.; XON CELLS, INC.
To: XON CELLS, INC.
Reel/Frame 034002/0712 →
CHANGE OF NAME Recorded Nov 22, 2013
From: MEDISTEM LABORATORIES, INC.
To: MEDISTEM INC.
Reel/Frame 031655/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2013
From: RIORDAN, NEIL H.
To: SGC HOLDINGS, INC.
Reel/Frame 031648/0292 →
CHANGE OF NAME Recorded Nov 21, 2013
From: SGC HOLDINGS, INC.
To: MEDISTEM LABORATORIES, INC.
Reel/Frame 031694/0330 →
Continuity (3)
Continuation 11353692 · Feb 14, 2006
Provisional Application 60653390 · Feb 15, 2005
Related Publication 20100261152A1 · Oct 14, 2010